We are pleased to announce our successful DCP submission for Desogestrel+Ethinylestradiol (0.15mg+0.02mg) film-coated tablets.
This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients.
Our Desogestrel+Ethinylestradiol 0.15mg/0.02mg film-coated tablets were developed in collaboration with one of our strategic partners, based on the reference brand Mercilon film-coated tablets. The product is a low-dose contraceptive used by women to prevent pregnancy.
According to IQVIA, Desogestrel+Ethinylestradiol (0.15mg+0.02mg) generated approximately $85mn in global sales in 2022.
Building on this accomplishment, Adalvo continues to expand their Women's Health portfolio. As a distinguished player in this domain, we are delighted to offer a wide range of products, as outlined below:
- Cyproterone + Ethinylestradiol, 2 mg + 0.035 mg
- Desogestrel, 75 mcg
- Desogestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
- Desogestrel + Ethinylestradiol, 0.15 mg + 0.03 mg
- Dienogest, 2 mg
- Drospirenone + Ethinylestradiol, 3 mg + 0.02 mg
- Drospirenone + Ethinylestradiol, 3 mg + 0.03 mg
- Levonorgestrel, 1.5 mg
- Levonorgestrel + Ethinylestradiol, 0.10 mg + 0.02 mg
- Levonorgestrel + Ethinylestradiol, 0.15 mg + 0.03 mg
- Norethisterone, 5 mg
- Norethisterone + Estradiol, 0.5 mg + 1 mg
Partner up now!
At Adalvo, there are no half measures – we arealways on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
marta.puig@adalvo.com - South Europe
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
arni.baldursson@adalvo.com - Head of Global BD&L
Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.